{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:15:30Z","timestamp":1790882130490,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We evaluated whether CT intensity and texture radiomics provide predictive value beyond simple volume dynamics for lesion-level response prediction in metastatic melanoma treated with immune checkpoint inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective multicenter study including 158 patients (1,626 lesions) from an internal cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009129 patients with standardized protocols) and an external cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200929 patients with heterogeneous protocols). The primary endpoint was binary lesion-level size response (clinical benefit vs. progressive disease) at the second follow-up. We trained and compared Random Forest classifiers to predict this endpoint using clinical variables, volumetric features, radiomics, and combined predictors derived from baseline and first follow-up imaging. Models were trained on the internal cohort using patient-grouped cross-validation and applied unchanged to the external cohort. Paired differences in AUC were assessed against a\u2009\u00b1\u20090.05 equivalence margin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline-only prediction of first follow-up response was near chance for all models. For predicting response at second follow-up, the volumetric model achieved an internal AUC of 0.84 [95% CI 0.78\u20130.88] and the radiomics model 0.86 [0.81\u20130.90]. In the external cohort, with 12 progression events, the volumetric and radiomics models achieved AUCs of 0.68 [0.50\u20130.85] and 0.68 [0.51\u20130.88], with no significant difference between any models. Organ-specific analysis showed no significant improvement from adding radiomics for any lesion site. Across all 288 radiomic features, the median absolute correlation with lesion volume was 0.37. Sensitivity analyses contained small or borderline gains that did not replicate externally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Volumetric features capture the primary predictive information for early lesion-level response, and CT radiomics showed no conclusive improvement over volume dynamics. Confirmation in larger independent cohorts is required before radiomic signatures can be recommended for this task.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40644-026-01135-4","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:34:49Z","timestamp":1790876089000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CT radiomics showed no improvement beyond volume dynamics for early lesion-level size response to immunotherapy in metastatic melanoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Seval","family":"Akbal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan Constantin","family":"Schepers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul V.","family":"Op gen Oorth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bleymehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Schroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Winneknecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devayani","family":"Machiraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius C.","family":"Holzschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin S.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wohlfeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ayx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan O.","family":"Schoenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Peter","family":"Schlemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas T.","family":"Rotkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"16","key":"1135_CR1","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019, Oct, 17;381(16):1535\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1910836.","journal-title":"N Engl J Med"},{"issue":"1","key":"1135_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025, Jan, 2;392(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2407417.","journal-title":"N Engl J Med"},{"key":"1135_CR3","doi-asserted-by":"publisher","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. The Lancet Oncol. 2017, Mar;18(3):e143\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(17)30074-8.","DOI":"10.1016\/S1470-2045(17)30074-8"},{"issue":"12","key":"1135_CR4","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017, Dec;14(12):749\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.141.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1135_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ejca.2011.11.036","volume":"48","author":"P Lambin","year":"2012","unstructured":"Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, Van Stiphout RGPM, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012, Mar;48(4):441\u201346. https:\/\/doi.org\/10.1016\/j.ejca.2011.11.036.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1135_CR6","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/annonc\/mdz108","volume":"30","author":"S Trebeschi","year":"2019","unstructured":"Trebeschi S, Drago SG, Birkbak NJ, Kurilova I, C\u01celin AM, Delli Pizzi A, et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann Oncol. 2019, Jun;30(6):998\u20131004. https:\/\/doi.org\/10.1093\/annonc\/mdz108.","journal-title":"Ann Oncol"},{"issue":"9","key":"1135_CR7","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","volume":"19","author":"R Sun","year":"2018","unstructured":"Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018, Sep;19(9):1180\u201391. https:\/\/doi.org\/10.1016\/S1470-2045(18)30413-3.","journal-title":"The Lancet Oncol"},{"key":"1135_CR8","doi-asserted-by":"publisher","unstructured":"Dercle L, McGale J, Sun S, Marabelle A, Yeh R, Deutsch E, et al. Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy. J Immunother Cancer. 2022, Sep;10(9):e005292. https:\/\/doi.org\/10.1136\/jitc-2022-005292.","DOI":"10.1136\/jitc-2022-005292"},{"issue":"4","key":"1135_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.18383\/j.tom.2016.00208","volume":"2","author":"JE Van Timmeren","year":"2016","unstructured":"Van Timmeren JE, Leijenaar RTH, Van Elmpt W, Wang J, Zhang Z, Dekker A, et al. Test-retest data for radiomics feature stability analysis: generalizable or study-specific? Tomography. 2016, Dec, 1;2(4):361\u201365. https:\/\/doi.org\/10.18383\/j.tom.2016.00208.","journal-title":"Tomography"},{"issue":"4","key":"1135_CR10","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.ijrobp.2018.05.053","volume":"102","author":"A Traverso","year":"2018","unstructured":"Traverso A, Wee L, Dekker A, Gillies R. Repeatability and reproducibility of radiomic features: a systematic review. Int J Radiat Oncol. 2018, Nov;102(4):1143\u201358. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.05.053.","journal-title":"Int J Radiat Oncol"},{"issue":"11","key":"1135_CR11","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1097\/RLI.0000000000000180","volume":"50","author":"D Mackin","year":"2015","unstructured":"Mackin D, Fave X, Zhang L, Fried D, Yang J, Taylor B, et al. Measuring computed tomography scanner variability of radiomics features: Invest Radiol. 2015. Nov;50(11):757\u201365. https:\/\/doi.org\/10.1097\/RLI.0000000000000180.","journal-title":"Invest Radiol"},{"issue":"9","key":"1135_CR12","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3390\/jpm11090842","volume":"11","author":"SA Mali","year":"2021","unstructured":"Mali SA, Ibrahim A, Woodruff HC, Andrearczyk V, M\u00fcller H, Primakov S, et al. Making radiomics more reproducible across scanner and imaging protocol variations: a review of harmonization methods. J Pers Med. 2021, Aug, 27;11(9):842. https:\/\/doi.org\/10.3390\/jpm11090842.","journal-title":"J Pers Med"},{"issue":"2","key":"1135_CR13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1148\/radiol.2020191145","volume":"295","author":"A Zwanenburg","year":"2020","unstructured":"Zwanenburg A, Valli\u00e8res M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020, May;295(2):328\u201338. https:\/\/doi.org\/10.1148\/radiol.2020191145.","journal-title":"Radiology"},{"issue":"2","key":"1135_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1148\/radiol.2018172361","volume":"288","author":"R Berenguer","year":"2018","unstructured":"Berenguer R, Pastor-Juan MDR, Canales-V\u00e1zquez J, Castro-Garc\u00eda M, Villas MV, Mansilla Legorburo F, et al. Radiomics of CT features may be nonreproducible and redundant: influence of CT acquisition parameters. Radiology. 2018, Aug;288(2):407\u201315. https:\/\/doi.org\/10.1148\/radiol.2018172361.","journal-title":"Radiology"},{"issue":"19","key":"1135_CR15","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.3390\/diagnostics13193065","volume":"13","author":"J McGale","year":"2023","unstructured":"McGale J, Hama J, Yeh R, Vercellino L, Sun R, Lopci E, et al. Artificial intelligence and radiomics: clinical applications for patients with advanced melanoma treated with immunotherapy. Diagnostics. 2023, Sep, 27;13(19):3065. https:\/\/doi.org\/10.3390\/diagnostics13193065.","journal-title":"Diagnostics"},{"key":"1135_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejca.2023.02.017","volume":"185","author":"LS Ter Maat","year":"2023","unstructured":"Ter Maat LS, Van Duin IAJ, Elias SG, Leiner T, Verhoeff JJC, Arntz ERAN, et al. CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma. Eur J Cancer. 2023, May;185:167\u201377. https:\/\/doi.org\/10.1016\/j.ejca.2023.02.017.","journal-title":"Eur J Cancer"},{"key":"1135_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.radonc.2018.10.027","volume":"130","author":"ML Welch","year":"2019","unstructured":"Welch ML, McIntosh C, Haibe-Kains B, Milosevic MF, Wee L, Dekker A, et al. Vulnerabilities of radiomic signature development: the need for safeguards. Radiother Oncol. 2019, Jan;130:2\u20139. https:\/\/doi.org\/10.1016\/j.radonc.2018.10.027.","journal-title":"Radiother Oncol"},{"issue":"1","key":"1135_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1471-2105-7-91","volume":"7","author":"S Varma","year":"2006","unstructured":"Varma S, Simon R. Bias in error estimation when using cross-validation for model selection. BMC Bioinf. 2006, Dec;7(1):91. https:\/\/doi.org\/10.1186\/1471-2105-7-91.","journal-title":"BMC Bioinf"},{"key":"1135_CR19","doi-asserted-by":"publisher","unstructured":"Kim H, Park CM, Lee M, Park SJ, Song YS, Lee JH, et al. Impact of reconstruction algorithms on CT radiomic features of pulmonary tumors: analysis of intra- and inter-reader variability and inter-reconstruction algorithm variability. Zeng, L, editor. PLoS One. 2016, Oct, 14;11(10):e0164924. https:\/\/doi.org\/10.1371\/journal.pone.0164924.","DOI":"10.1371\/journal.pone.0164924"},{"issue":"1","key":"1135_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2967\/jnmt.124.268252","volume":"53","author":"P Dwivedi","year":"2025","unstructured":"Dwivedi P, Barage S, Jha AK, Choudhury S, Rangarajan V. Robustness of18 F-FDG PET radiomic features in lung cancer: impact of advanced reconstruction algorithm. J Nucl Med Technol. 2025, Mar;53(1):50\u201356. https:\/\/doi.org\/10.2967\/jnmt.124.268252.","journal-title":"J Nucl Med Technol"},{"issue":"12","key":"1135_CR21","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.3390\/cancers14122992","volume":"14","author":"F Peisen","year":"2022","unstructured":"Peisen F, H\u00e4nsch A, Hering A, Brendlin AS, Afat S, Nikolaou K, et al. Combination of whole-body baseline CT radiomics and clinical parameters to predict response and survival in a stage-IV melanoma cohort undergoing immunotherapy. Cancers. 2022, Jun, 17;14(12):2992. https:\/\/doi.org\/10.3390\/cancers14122992.","journal-title":"Cancers"},{"issue":"16","key":"1135_CR22","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1158\/1078-0432.CCR-20-0020","volume":"26","author":"L Basler","year":"2020","unstructured":"Basler L, Gabry\u015b HS, Hogan SA, Pavic M, Bogowicz M, Vuong D, et al. Radiomics, tumor volume, and blood biomarkers for early prediction of pseudoprogression in patients with metastatic melanoma treated with immune checkpoint inhibition. Clin Cancer Res. 2020, Aug, 15;26(16):4414\u201325. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0020.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1135_CR23","doi-asserted-by":"publisher","first-page":"31668","DOI":"10.1038\/s41598-024-81188-2","volume":"14","author":"LS Ter Maat","year":"2024","unstructured":"Ter Maat LS, De Mooij RAJ, Van Duin IAJ, Verhoeff JJC, Elias SG, Leiner T, et al. Deep learning on CT scans to predict checkpoint inhibitor treatment outcomes in advanced melanoma. Sci Rep. 2024, Dec, 30;14(1):31668. https:\/\/doi.org\/10.1038\/s41598-024-81188-2.","journal-title":"Sci Rep"},{"key":"1135_CR24","doi-asserted-by":"publisher","unstructured":"Brendlin AS, Peisen F, Almansour H, Afat S, Eigentler T, Amaral T, et al. A machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma. J Immunother Cancer. 2021, Nov;9(11):e003261. https:\/\/doi.org\/10.1136\/jitc-2021-003261.","DOI":"10.1136\/jitc-2021-003261"},{"issue":"3","key":"1135_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jamaoncol.2021.6818","volume":"8","author":"L Dercle","year":"2022","unstructured":"Dercle L, Zhao B, G\u00f6nen M, Moskowitz CS, Firas A, Beylergil V, et al. Early readout on overall survival of patients with melanoma treated with immunotherapy using a novel imaging analysis. JAMA Oncol. 2022, Mar, 1;8(3):385. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6818.","journal-title":"JAMA Oncol"},{"issue":"15","key":"1135_CR26","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.3390\/cancers16152669","volume":"16","author":"F Peisen","year":"2024","unstructured":"Peisen F, Gerken A, Hering A, Dahm I, Nikolaou K, Gatidis S, et al. Can delta radiomics improve the prediction of best overall response, progression-free survival, and overall survival of melanoma patients treated with immune checkpoint inhibitors? Cancers. 2024, Jul, 26;16(15):2669. https:\/\/doi.org\/10.3390\/cancers16152669.","journal-title":"Cancers"},{"issue":"11","key":"1135_CR27","doi-asserted-by":"publisher","first-page":"6905","DOI":"10.1007\/s00330-025-11637-7","volume":"35","author":"WA Noortman","year":"2025","unstructured":"Noortman WA, Vriens D, Bussink J, Meijer TWH, Aarntzen EHJG, Deroose CM, et al. Multicollinearity and redundancy of the PET radiomic feature set. Eur Radiol. 2025, May, 7;35(11):6905\u201316. https:\/\/doi.org\/10.1007\/s00330-025-11637-7.","journal-title":"Eur Radiol"},{"issue":"4","key":"1135_CR28","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s13246-025-01625-y","volume":"48","author":"P Dwivedi","year":"2025","unstructured":"Dwivedi P, Barage S, Singh R, Jha A, Choudhury S, Agrawal A, et al. PET-based radiomic analysis in multicentre lung cancer study and impact of feature domain harmonization. Phys Eng Sci Med. 2025, Dec;48(4):1841\u201351. https:\/\/doi.org\/10.1007\/s13246-025-01625-y.","journal-title":"Phys Eng Sci Med"},{"issue":"2","key":"1135_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s13139-025-00922-4","volume":"60","author":"P Dwivedi","year":"2026","unstructured":"Dwivedi P, Barage S, Jha A, Agrawal A, Singh R, Choudhury S, et al. Artificial intelligence assisted 18F-FDG PET radiomics in classifying histological subtypes of lung cancer: systematic review and meta-analysis. Nucl Med Mol Imag. 2026, Apr;60(2):79\u201392. https:\/\/doi.org\/10.1007\/s13139-025-00922-4.","journal-title":"Nucl Med Mol Imag"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01135-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01135-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01135-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:36:49Z","timestamp":1790879809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01135-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1135"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01135-4","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"11 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective bicentric study was conducted in accordance with the Declaration of Helsinki and relevant institutional guidelines and was approved by the responsible local ethics committees (reference numbers 2024\u2013809 and S-415\/2024). The requirement for written informed consent was waived by the ethics committees owing to the retrospective nature of the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"138"}}